Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13405231 | 1.00 | TSHR (0.56) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL757089 | 0.91 | TDP1 (0.47) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL23225393 | 0.86 | IDO1 (0.41) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL20075977 | 0.85 | IDO1 (0.43) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL759464 | 0.85 | CA12 (0.55) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL17696336 | 0.84 | TSHR (0.63) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL14102322 | 0.84 | TSHR (0.68) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL22276648 | 0.84 | TDP1 (0.56) | ADRB2HTR1ATDP1CA12CA1 | |
| SCHEMBL22276641 | 0.84 | TDP1 (0.56) | ADRB2HTR1ATDP1CA12CA1 | |
| SCHEMBL12885084 | 0.84 | TDP1 (0.56) | ADRB2HTR1ATDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-11072741-B2 | Optically anisotropic layer, method for producing the optically anisotropic layer, a laminate, polarizing plate, display device, liquid crystal compound, method for producing the liquid crystal compound, and carboxylic acid compound | FUJIFILM CORPORATION (JP) | 2021-07-27 | — | — | US | disclosed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170349828-A1 | POLYMERIZABLE COMPOSITION, FILM, AND HALF MIRROR FOR DISPLAYING PROJECTION IMAGE | FUJIFILM CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349828-A1 | POLYMERIZABLE COMPOSITION, FILM, AND HALF MIRROR FOR DISPLAYING PROJECTION IMAGE | FUJIFILM CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2012024526-A2 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011104169-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | TSHR 2340/4885ALDH1A1 4396/4885TP53 1975/4885 |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | TSHR 2452/4885ALDH1A1 4718/4885TP53 2831/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | TSHR 1212/4885ALDH1A1 1838/4885TP53 3555/4885 |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | TSHR 2452/4885ALDH1A1 4718/4885TP53 2831/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | TSHR 2452/4885ALDH1A1 4718/4885TP53 2831/4885 |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | TSHR 2594/4885ALDH1A1 3222/4885TP53 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.